Dr. Reddy's Laboratories Limited (DRREDDY) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Total Revenue Chart for Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (DRREDDY) revenue for FY2026 was INR 335.9B, a 3.2% change from FY2025. Dr. Reddy's Laboratories Limited's revenue grew from INR 10.9B in 2001 to INR 335.9B in 2026 (2972.1% over 25 years). Earnings per share grew from INR 25.17 in 2014 to INR 67.79 in 2025 (169.3%). Revenue compound annual growth rate: 5-year CAGR of 12.1%, 10-year CAGR of 8.1%, 20-year CAGR of 14.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (Indian Rupees)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
₹980.44B
Implied Share Price
₹1177.00
Enterprise Value
₹978.80B
Revenue (TTM)
₹331.19B
EBITDA
₹54.67B
Profit Margin
10.00%
Trailing P/E
29.76
Forward P/E
26.95
Price/Book (MRQ)
2.57
Price/Sales (TTM)
2.96
EV/EBITDA
14.68
EV/Revenue
2.96
Dividend Yield
0.68%
Book Value
₹460.31
Free Cash Flow (FY2026)
₹30.51B
Free Cash Flow Yield
3.11%

Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.